Innovent Biologics, Inc. (HKEX: 01801), a global leader in biopharmaceutical innovation, has announced that it will showcase several clinical trial results for its novel GLP-1R/GCGR dual agonist, Mazdutide, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain. The conference will take place from September 9 to 13, 2024.
Among the key presentations, the Phase 3 trial results of Mazdutide in Chinese adults with type 2 diabetes, known as the DREAMS-2 study, will be featured as a late-breaking oral presentation. This presentation is scheduled for September 11 from 4:15 PM to 4:30 PM CEST. The study, titled “Mazdutide vs Dulaglutide in Patients with Type 2 Diabetes (DREAMS-2): A Randomized, Open-label, 28-week Phase 3 Trial,” aims to highlight Mazdutide’s effectiveness compared to Dulaglutide.
Further details of the conference presentations include:
“Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)”
Abstract #149, Oral Presentation, September 12, 11:45 AM – 12:00 PM CEST, presented by Prof. Linong Ji from Peking University People’s Hospital.
“Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity: An Exploratory Analysis of GLORY-1”
Abstract #744, Short Oral Presentation, September 10, 12:30 PM CEST, presented by Prof. Leili Gao of Peking University People’s Hospital.
“A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI≥30 kg/m²”
Abstract #733, Short Oral Presentation, September 12, 2:00 PM CEST, presented by Prof. Hongwei Jiang from the First Affiliated Hospital of Henan University of Science and Technology.
Dr. Lei Qian, Vice President of Clinical Development at Innovent, expressed enthusiasm about the upcoming presentations. “We are thrilled to present the DREAMS-2 study results at EASD. Mazdutide represents a significant advancement as the first GLP-1R/GCGR dual agonist to complete a Phase 3 diabetes study, showcasing its superior efficacy in blood sugar reduction and weight loss compared to Dulaglutide. The conference will also feature important data on Mazdutide’s effects on weight loss and glucose control, as well as its benefits on liver health.”
About Mazdutide (IBI362)
Mazdutide, a dual agonist targeting GLP-1R and GCGR, was licensed exclusively to Innovent by Eli Lilly and Company. This compound, an analogue of mammalian oxyntomodulin, enhances insulin secretion, lowers blood glucose levels, and aids in weight reduction. It also shows promise in increasing energy expenditure and improving liver fat metabolism.
The drug has two New Drug Applications (NDAs) under review by China’s National Medical Products Administration (NMPA), focusing on chronic weight management in obesity and glycemic control in type 2 diabetes. Currently, Innovent is conducting five Phase 3 trials of Mazdutide, including studies on weight management and diabetes in various patient populations.
About Innovent
Founded in 2011, Innovent Biologics is dedicated to providing high-quality, affordable biologics. The company focuses on developing therapies for cancer, cardiovascular, metabolic, autoimmune, and eye diseases. Innovent’s portfolio includes 11 market products, with additional drugs in various stages of development. The company collaborates with numerous global healthcare leaders to advance biopharmaceutical innovation.
Forward-Looking Statements
This press release may contain forward-looking statements subject to significant risks and uncertainties. The company does not commit to updating these statements regularly. Actual outcomes may differ based on changes in business conditions, competitive landscape, and other factors.
Related topics:
Escalating Global Diabetes Crisis: A Growing Threat in Developing Nations
Debunking Blood Sugar Myths: The Facts You Need to Know
Cutting Nighttime Light: A Simple Strategy to Lower Diabetes Risk
